

Therapeutic agent for sepsis and MOF


Masahiro Nishibori, M.D., Ph.D.

Okayama Univ Grad Schl Med, Dent & Pharmaceut Sci.

Development of therapy for sepsis by histidine-rich glycoprotein (HRG)


Effects of HRG on human neutrophils

Control




Scanning electron microscopy

HRG-treated



Fluorescence labelling



● **HRG effects**

- Induction of spherical shape
- Loss of surface microvilli
- Decrease in adhesion to VEC
- Inhibition of ROS production

• **Recombinant human HRG**

• **Patent**
PCT/JP2013/64779
Therapeutic agent for sepsis



Diseases involve excessive neutrophil activation

Sepsis

MOF

Trauma ARDS Brain trauma

IBD AKI



- **Therapeutic**
Recombinant human HRG
CHO, HEK293
- **Applications**
Diagnosis
Severity evaluation
Prognosis estimation
- **Perspective**
Other effector cells
Other applications
Collection of human data